HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE)

Trial Profile

HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Lanadelumab (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; Registrational
  • Acronyms HELP Study ExtensionTM
  • Sponsors Dyax; Shire
  • Most Recent Events

    • 27 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jan 2017 Planned number of patients changed from 150 to 220.
    • 10 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top